Neural mechanisms underlying nicotine addiction: Acute positive reinforcement and withdrawal

Nicotine and Tobacco Research

Volumn 2, Issue 1, 2000, Pages 19-37

  Watkins, Shelly S ^a,b   Koob, George F ^a,c   Markou, Athina ^a,d  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; NEUROPEPTIDE;

ANIMAL; BIOLOGICAL MODEL; HUMAN; MENTAL DISEASE; METABOLISM; PATHOPHYSIOLOGY; REINFORCEMENT; REVIEW; TOBACCO DEPENDENCE; WITHDRAWAL SYNDROME;

ANIMALS; HUMANS; MENTAL DISORDERS; MODELS, NEUROLOGICAL; NEUROPEPTIDES; NEUROTRANSMITTER AGENTS; REINFORCEMENT (PSYCHOLOGY); SUBSTANCE WITHDRAWAL SYNDROME; TOBACCO USE DISORDER;

EID: 0034135820     PISSN: 14622203     EISSN: None     Source Type: Journal    
DOI: 10.1080/14622200050011277     Document Type: Review

References (226)

1. Acri JB, Brown KJ, Saah MI, Grunberg NE. 1995. Strain and age differences in acoustic startle responses and effects of nicotine in rats. Pharmacology, Biochemistry and Behavior 50:191-198.
2. Adler LE, Pachtman E, Franks R, Pecevich M, Waldo MC, Freedman R. 1982. Neuropsychological evidence for a defect in neuronal mechanisms involved in sensory gating in schizophrenia. Biological Psychiatry 17:639-654.
3. Adler LE, Hoffer LD, Wiser A, Freedman R. 1993. Normalization of auditory physiology by cigarette smoking in schizophrenic patients. American Journal of Psychiatry 150:1856-1861.
4. Ahmed SH, Koob GF. 1998. Transition from moderate to excessive drug intake: change in hedonic set point. Science 282:298-300.
5. Alheid GF, Heimer L. 1988. New perspectives in basal forebrain organization of special relevance for neuropsychiatric disorders: the striatopallidal, amygdaloid, and corticopetal components of substantia inominata. Neuroscience 27:1-39.
6. Alkondon M, Albuquerque EX. 1993. Diversity of nicotinic acetylcholine receptors in rat hippocampal neurons I. Pharmacological and functional evidence for distinct structural subtypes. Journal of Pharmacology and Experimental Therapeutics 265:1455-1473.
7. American Psychiatric Association. 1994. Diagnostic and Statistical Manual of Mental Disorders (4th edn). American Psychiatric Press, Washington, DC.
8. Arneric SP, Sullivan JP, Williams M. 1995. Neuronal nicotinic acetylcholine receptors: novel targets for central nervous system therapeutics. In Bloom FE, Kupfer DJ, eds. Psychopharmacology: The Fourth Generation of Progress. New York, Raven Press, pp. 95-110.
9. Ascher JA, Cole JO, Colin JN, Feighner JP, Ferris RM, Fibiger HC, Golden RN, Martin P, Potter WZ, Richelson E, Sulser F. 1995. Buproprion: a review of its mechanism of antidepressant activity. Journal of Clinical Psychiatry 56:395-401.
10. Baldo BA, Jain K, Veraldi L, Koob GF, Markou A. 1999. A dopamine D1 agonist elevates self-stimulation thresholds: comparison to other dopamine-selective drugs. Pharmacology, Biochemistry and Behavior 62:659-672.
11. Baldwin HA, Rassnick S, Rivier J, Koob GF, Britton KT. 1991. CRF antagonist reverses the 'anxiogenic' response to ethanol withdrawal in the rat. Psychopharmacology 103:227-232.
12. Balfour DJ. 1984. Nicotine and the tobacco smoking habit. In Balfour DJ, ed. International Encyclopedia of Pharmacology and Therapeutics. New York: Pergamon Press, pp. 61-74.
13. Battaglia G, Bruno V, Ngomba RT, Di Grezia R, Copani A, Nicoletti F. 1998. Selective activation of group-II metabotropic glutamate receptors is protective against excitotoxic neuronal death. European Journal of Pharmacology 356:271-274.
14. Bauco P Wise RA. 1994. Potentiation of lateral hypothalamic and midline mesencephalic brain stimulation reinforcement by nicotine: examination of repeated treatment. Journal of Pharmacology and Experimental Therapeutics 271:294-301.
15. Benowitz NL. 1988. Pharmacologic aspects of cigarette smoking and nicotine addiction. New England Journal of Medicine 319:1318-1330.
16. Benowitz NL. 1996. Pharmacology of nicotine: addiction and therapeutics. Annual Review of Pharmacology and Toxicology 36:597-613.
17. Benwell ME, Balfour DJ. 1979. Effects of nicotine administration and its withdrawal on plasma corticosterone and brain 5-hydroxyindoles. Psychopharmacology 63:7-11.
18. Benwell ME, Balfour DJ. 1992. The effects of acute and repeated nicotine treatment on nucleus accumbens dopamine and locomotor activity. British Journal of Pharmacology 105:849-856.
19. 3H] nicotine binding sites in human brain. Journal of Neurochemistry 50:1243-1247.
20. Benwell ME, Balfour DJ, Anderson JM. 1990. Smoking-associated changes in the serotonergic systems of discrete regions of human brain. Psychopharmacology 102:68-72.
21. Benwell ME, Balfour DJ, Lucchi HM. 1993. Influence of tetrodotoxin and calcium changes in extracellular dopamine levels evoked by systemic nicotine. Psychopharmacology 112:467-474.
22. Bhat RV, Marks MJ, Collins AC. 1994. Effects of chronic nicotine infusion on kinetics of high-affinity nicotine binding. Journal of Neurochemistry 62:574-581.
23. Bolam JP, Francis CM, Henderson Z. 1991. Cholinergic input to dopaminergic neurons in the substantia nigra: a double immunohistochemical study. Neuroscience 41:483-494.
24. Boyadjieva NI, Sarkar DK. 1997. The secretory response of hypothalamic β-endorphin neurons to acute and chronic nicotine treatments following nicotine withdrawal. Life Sciences 61:PL59-PL66.
25. Breslau N, Kilbey MM, Andreski P. 1993. Nicotine dependence and major depression: new evidence from a prospective investigation. Archives of General Psychiatry 50:31-35.
26. Bruno V, Battaglia G, Copani A, Giffard RG, Raciti G, Raffaele R, Shinozaki H, Nicoletti F. 1995. Activation of class II or III metabotropic glutamate receptors protects cultured cortical neurons against excitotoxic degeneration. European Journal of Neuroscience 7:1906-1913.
27. Bubser M, Koch M 1994. Prepulse inhibition of the acoustic startle response of rats is reduced by 6-hydroxydopamine lesions of the medial prefrontal cortex. Psychopharmacology 113:487-492.
28. Buisson A, Yu SP, Choi DW. 1996. DCG-IV selectively attenuates rapidly triggered NMDA-induced neurotoxicity in cortical neurons. European Journal of Neuroscience 8:138-143.
29. Caine SB, Koob GF. 1994. Effects of mesolimbic dopamine depletion on responding maintained by cocaine and food. Journal of the Experimental Analysis of Behavior 61:213-221.
30. Caine SB, Heinrichs SC, Coffin VL, Koob GF. 1995. Effects of dopamine D-1 antagonist SCH23390 microinjected into the accumbens, amygdala, or striatum on cocaine self-administration in the rat. Brain Research 692:47-56.
31. Cesselin F. 1995. Opioid and anti-opioid peptides. Fundamental and Clinical Pharmacology 9:409-433.
32. Changeux JP, Devillers-Thiery A, Chemouilli P. 1984. Acetylcholine receptor: an allosteric protein. Science 225:1335-1345.
33. Chergui K, Charlety PJ, Akaoka H, Saunier CF, Brunet JL, Buda M, Svensson TH, Chouvet G. 1993. Tonic activation of NMDA receptors causes spontaneous burst discharge of rat midbrain dopamine neurons in vivo. European Journal of Neuroscience 5:137-144.
34. Churchill L, Dilts RP, Kalivas PW. 1992. Autoradiographic localization of gamma-aminobutyric acid A receptors within the ventral tegmental area. Neurochemical Research 17:101-106.
35. Clarke PBS, Kumar R. 1983. The effects of nicotine on locomotor activity in non-tolerant and tolerant rats. British Journal of Pharmacology 78:329-337.
36. Clarke PBS, Pert A. 1985. Autoradiographic evidence for nicotinic receptors on nigrostriatal and mesolimbic dopaminergic neurons. Brain Research 348:355-358.
37. Clarke PBS, Hommer DW, Pert A, Skirboll LR. 1987. Innervation of substantia nigra neurons by cholinergic afferents from pedunculopontine nucleus in the rat: neuroanatomical and electrophysiological evidence. Neuroscience 23:1011-1019.
38. Clementz BA, Geyer MA, Braff DL. 1997. P50 suppression among schizophrenia and normal comparison subjects: a methodological analysis. Biological Psychiatry 41:1035-1044.
39. Collins AC, Bhat RV, Pauly JR, Marks MJ. 1990. Modulation of nicotine receptors by chronic exposure to nicotinic agonists and antagonists. In Bock G, Marsh J, eds. The Biology of Nicotine Dependence (Series title: Ciba Foundation Symposium, Vol. 152). New York: John Wiley and Sons, pp. 87-105.
40. Coppen A. 1967. The biochemistry of affective disorders. British Journal of Psychiatry 113:1237-1264.
41. Corrigall WA, Coen KM. 1989. Nicotine maintains robust self-administration in rats on a limited-access schedule. Psychopharmacology 99:473-478.
42. Corrigall WA, Coen KM. 1991. Selective dopamine antagonists reduce nicotine self-administration. Psychopharmacology 104:171-176.
43. 3 antagonists ICS 205-930 and MDL 72222. Pharmacology, Biochemistry and Behavior 49:67-71
44. Corrigall WA, Franklin KBJ, Coen KM, Clarke PBS. 1992. The mesolimbic dopaminergic system is implicated in the reinforcing effects of nicotine. Psychopharmacology 107:285-289.
45. Corrigall WA, Coen KM, Adamson KL. 1994. Self-administered nicotine activates the mesolimbic dopamine system through the ventral tegmental area. Brain Research 653:278-284.
46. Corringer PJ, Bertrand S, Bohler S, Edelstein SJ, Changeux JP, Bertrand D. 1998. Critical elements determining diversity in agonist binding and desensitization on neuronal nicotinic acetylcholine receptors. Journal of Neuroscience 18:648-657.
47. Crippens D, Robinson TE. 1994. Withdrawal from morphine or amphetamine: different effects on dopamine in the ventral-medial striatum studied with microdialysis. Brain Research 650:56-62.
48. Cullum CM, Harris JG, Waldo MC, Smernoff E, Madison A, Nagamoto HT, Griffith J, Adler LE, Freedman R. 1993. Neurophysiological and neuropsychological evidence for attentional dysfunction in schizophrenia. Schizophrenia Research 10:131-141.
49. Curzon P, Kim DJ, Decker MW. 1994. Effect of nicotine, lobeline, and mecamylamine on sensory gating in the rat. Pharmacology, Biochemistry and Behavior 49:877-882.
50. Dalack GW, Meador-Woodruff JH. 1996. Smoking, smoking withdrawal and schizophrenia: case reports and a review of the literature. Schizophrenia Research 22:133-141.
51. Dalack GW, Healy DJ, Meador-Woodruff JH. 1998. Nicotine dependence in schizophrenia: clinical phenomena and laboratory findings. American Journal of Psychiatry 155:1490-1501.
52. Dani JA, Heinemann S. 1996. Molecular and cellular aspects of nicotine abuse. Neuron 16:905-908.
53. Davenport KE, Houdi AA, VanLoon GR. 1990. Nicotine protects against mu-opioid receptor antagonism by beta-funaltrexamine: evidence for nicotine-induced release of endogenous opioid. Neuroscience Letters 113:40-46.
54. de Olmos JS, Alheid GF, Beltramino CA. 1985. Amygdala. In Paxinos G, ed. The Rat Nervous System, Vol 1. New York: Academic Press, pp. 223-334.
55. Decina P, Caracci G, Sandik R, Berman W, Mukherjee S, Scapicchio P. 1990. Cigarette smoking and neuroleptic-induced parkinsonism. Biological Psychiatry 28:502-508.
56. Delgado PL, Charney DS, Price LH, Aghajanian GK, Landis H, Heninger GR. 1990. Serotonin function and the mechanism of antidepressant action: reversal of antidepressant-induced remission by rapid depletion of plasma tryptophan. Archives of General Psychiatry 47:411-418.
57. Delgado PL, Price LH, Miller HL, Salomon RM, Licinio J, Krystal JH, Heninger GR, Charney DS. 1991. Rapid serotonin depletion as a provocative challenge test for patients with major depression: relevance to antidepressant action and the neurobiology of depression. Psychopharmacology Bulletin 27:321-330.
58. Dewey SL, Brodie JD, Gerasimov M, Horan B, Gardner EL, Ashby CR Jr. 1999. A pharmacologic strategy for the treatment of nicotine addiction. Synapse 31:76-86.
59. Doherty K, Kinnunen T, Militello FS, Garvey AJ. 1995. Urges to smoke during the first month of abstinence: relationship to relapse and predictors. Psychopharmacology 119:171-178.
60. Edwards NB, Murphy JK, Downs AD, Ackerman BJ, Rosenthal TL. 1989. Doxepin as an adjunct to smoking cessation: a double-blind pilot study. American Journal of Psychiatry 146:373-376.
61. Epping-Jordan MP, Markou A, Koob GF. 1998a. The dopamine D-1 receptor antagonist SCH23390 injected into the dorsolateral bed nucleus of the stria terminalis decreased cocaine reinforcement in the rat. Brain Research 784:105-115.
62. Epping-Jordan MP, Watkins SS, Koob GF, Markou A. 1998b. Dramatic decreases in brain reward function during nicotine withdrawal. Nature 393:76-79.
63. Flores CM, Rogers SW, Pabreza LA, Wolfe BB, Kellar KJ. 1992. A subtype of nicotinic cholinergic receptor in rat brain is composed of alpha4-subunit and beta2-subunit and is upregulated by chronic nicotine treatment. Molecular Pharmacology 41:31-37.
64. Freedman E, Hall M, Adler LE, Leonard S. 1995. Evidence in postmortem tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia. Biological Psychiatry 38:22-33.
65. Freedman R, Adler LE, Myles-Worsley M, Nagamoto HT, Miller C, Kisley M, McRae K, Cawthra E, Waldo M. 1996. Inhibitory gating of an evoked response to repeated auditory stimuli in schizophrenic and normal subjects: human recordings, computer simulation, and an animal model. Archives of General Psychiatry 53:1114-1121.
66. Fung YK, Schmid MJ, Anderson TM, Lau Y-S. 1996. Effects of nicotine withdrawal on central dopaminergic systems. Pharmacology, Biochemistry and Behavior 53:635-640.
67. Geyer MA, Braff DL. 1987. Startle habituation and sensorimotor gating in schizophrenia and related animal models. Schizophrenia Bulletin 13:643-668.
68. Geyer MA, Puerto A, Menkes DB, Segal DS, Mandell AJ. 1976. Behavioral studies following lesions of the mesolimbic and mesostriatal serotonergic pathways. Brain Research 106:256-270.
69. Geyer MA, Peterson LR, Rose GJ. 1980. Effects of serotonergic lesions on investigatory responding by rats in a holeboard. Behavioral and Neural Biology 30:160-177.
70. Geyer MA, Wilkinson LS, Humby T, Robbins TW 1993. Isolation rearing of rats produces a deficit in prepulse inhibition of acoustic startle similar to that in schizophrenia. Biological Psychiatry 34:361-372.
71. Giorguieff-Chesselet MF, Kemel ML, Wandscheer D, Glowinski J. 1979. Regulation of dopamine release by presynaptic nicotinic receptors in rat striatal slices: effects of nicotine in a low concentration. Life Sciences 25:1257-1262.
72. Glassman AH. 1993. Cigarette smoking: implications for psychiatric illness. American Journal of Psychiatry 150:546-553.
73. Glassman AH, Stetner F, Walsh BT. 1988. Heavy smokers, smoking cessation, and clonidine: results of a double-blind, randomized trial. Journal of the American Medical Association 259:2863-2866.
74. Glassman AH, Helzer JE, Covey LS, Cottler LB, Stetner F, Tipp JE, Johnson J. 1990. Smoking, smoking cessation, and major depression. Journal of the American Medical Association 264:1546-1549.
75. Goff DC, Henderson DC, Amico E. 1992. Cigarette smoking in schizophrenia: relationship to psychopathology and medication side effects. American Journal of Psychiatry 149:1189-1194.
76. Gray R, Rajan AS, Radcliffe KA, Yakehiro M, Dani JA. 1996. Hippocampal synaptic transmission enhanced by low concentrations of nicotine. Nature 383:713-716.
77. Grenhoff J, Aston-Jones G, Svensson TH. 1986. Nicotinic effects on the firing pattern of midbrain dopamine neurons. Acta Physiologica Scandinavica 128:351-358.
78. Griffith JM, O'Neill JE, Petty F, Garver D, Young D, Freedman R. 1998. Nicotinic receptor desensitization and sensory gating deficits in schizophrenia. Biological Psychiatry 44:98-106.
79. Heimer L, Alheid GF. 1991. Piecing together the puzzle of forebrain anatomy. In Napier TC, Kalivas PW, Hanin I, eds. The Basal Forebrain: Anatomy to Function (Series title: Advances in Experimental Medicine and Biology, Vol. 295). New York: Plenum Press, pp. 1-42.
80. Heimer L, Alheid GF, Zabaorszky L. 1985. The basal ganglia. In Paxinos G, ed. The Rat Nervous System. Sydney: Academic Press, pp. 37-74.
81. Heimer L, Zahm DS, Churchill L, Kalivas PW, Wohltmann C. 1991. Specificity in the projection patterns of accumbal core and shell in the rat. Neuroscience 41:89-125.
82. Heinrichs SC, Menzaghi F, Schulteis G, Koob GF, Stinus L. 1995. Suppression of corticotropin-releasing factor in the amygdala attenuates aversive consequences of morphine withdrawal. Behavioral Pharmacology 6:74-80.
83. Helton DR, Modlin DL, Tizzano JP, Rasmussen K. 1993. Nicotine withdrawal: a behavioral assessment using schedule controlled responding, locomotor activity, and sensorimotor reactivity. Psychopharmacology 113:205-210.
84. Helton DR, Tizzano JP, Monn JA, Schoepp DD, Kallman MJ. 1997. LY354740: A metabotropic glutamate receptor agonist which ameliorates symptoms of nicotine withdrawal in rats. Neuropharmacology 36:1511-1516.
85. Henry JL. 1986. Role of circulating opioids in the modulation of pain. Annals of the New York Academy of Sciences 467:169-181.
86. Herz A. 1997. Endogenous opioid systems and alcohol addiction. Psychopharmacology 129:99-111.
87. Hildebrand BE, Nomikos GG, Bondjers C, Nisell M, Svensson TH. 1997. Behavioral manifestations of the nicotine abstinence syndrome in the rat: peripheral versus central mechanisms. Psychopharmacology 129:348-356.
88. Hildebrand BE, Nomikos GG, Hertel P, Schilstrom B, Svensson TH. 1998. Reduced dopamine output in the nucleus accumbens but not in the medial prefrontal cortex in rats displaying a mecamylamine-precipitated nicotine withdrawal syndrome. Brain Research 779:214-225.
89. Hildebrand BE, Panagis G, Svensson TH, Nomikos GG. 1999. Behavioral and biochemical manifestations of mecamylamine-precipitated nicotine withdrawal in the rat: role of nicotinic receptors in the ventral tegmental area. Neuropsychopharmacology 21:560-574.
90. Houdi AA, Pierzchala K, Marson L, Palkovits M, VanLoon GR. 1991. Nicotine-induced alteration in try-gly-gly and met-enkephalin in discrete brain nuclei reflects altered enkephalin neuron activity. Peptides 12:161-166.
91. Hsu YN, Amin J, Weiss DS, Wecker L. 1996. Sustained nicotine exposure differentially affects alpha 3 beta 2 and alpha 4 beta 2 neuronal nicotinic receptors expressed in Xenopus oocytes. Journal of Neurochemistry 66:667-675.
92. Hu XT, White FJ. 1996. Glutamate receptor regulation of rat nucleus accumbens neurons in vivo. Synapse 23:208-218.
93. Hughes JR. 1992. Tobacco withdrawal in self-quitters. Journal of Consulting and Clinical Psychology 60:689-697.
94. Hughes JR, Hatsukami DK, Pickens RW, Krahn D, Malin S, Luknic A. 1984. Effect of nicotine on the tobacco withdrawal syndrome. Psychopharmacology 83:82-87.
95. Hughes JR, Hatsukami DK, Mitchell JE, Dahlgren LA. 1986. Prevalence of smoking among psychiatric outpatients. American Journal of Psychiatry 143:993-997.
96. Hughes JR, Gust SW, Skoog K, Keenan RM, Fenwick JW. 1991. Symptoms of tobacco withdrawal: a replication and extension. Archives of General Psychiatry 48:52-59.
97. Hurt RD, Sachs DPL, Glover ED, Offord KP, Johnston JA, Dale LC, Khayrallah MA, Schroeder DR, Glover PN, Sullivan CR, Croghan IT, Sullivan PM. 1997. A comparison of sustained-release buproprion and placebo for smoking cessation. New England Journal of Medicine 337:1195-1202.
98. Huston-Lyons D, Kornetsky C. 1992. Effects of nicotine on the threshold for rewarding brain stimulation in rats. Pharmacology, Biochemistry and Behavior 41:755-759.
99. Jarvik ME. 1991. Beneficial effects of nicotine. British Journal of Addiction 86:571-575.
100. Jibson MD, Tandon R. 1998. New atypical antipsychotic medications. Journal of Psychiatric Research 32:215-228.
101. Jorenby DE, Leischow SJ, Nides MA, Rennard SI, Johnston JA, Hughes AR, Smith SS, Muramoto ML, Daughton DM, Doan K, Fiore MC, Baker TB. 1999. A controlled trial of sustained-release buproprion, a nicotine patch, or both for smoking cessation. New England Journal of Medicine 340:685-691.
102. Kalivas PW, Churchill L, Klitenick MA. 1993. GABA and enkephalin projection from the nucleus accumbens and ventral pallidum to the ventral tegmental area. Neuroscience 57:1047-1060.
103. Karras A, Kane JM. 1980. Naloxone reduces cigarette smoking. Life Sciences 27:1541-1545.
104. Koob GF. 1996. Drug addiction: the yin and yang of hedonic homeostasis. Neuron 16:893-896.
105. Koob GF, Bloom FE. 1988. Cellular and molecular mechanisms of drug dependence. Science 242:715-723.
106. Koob GF, LeMoal M. 1997. Drug abuse: hedonic homeostatic dysregulation. Science 278:52-58.
107. Koob GF, Markou A, Weiss F, Schulteis G. 1993. Opponent process and drug dependence: neurobiological mechanisms. Seminars in the Neurosciences 5:351-358.
108. Koob GF, Heinrichs SC, Menzaghi F, Merlo Pich E, Britton KT. 1994. Corticotropin-releasing factor, stress and behavior. Seminars in the Neurosciences 6:221-229.
109. Koob GF, Sanna PP, Bloom FE. 1998. Neuroscience of addiction. Neuron 21:467-476.
110. Kornetsky C, Esposito RU. 1981. Reward and detection thresholds for brain stimulation: dissociative effects of cocaine. Brain Research 209:496-500.
111. Kreek MJ, Koob GF. 1998. Drug dependence: stress and dysregulation of brain reward pathways. Drug and Alcohol Dependence 51:23-47.
112. Krishnan-Sarin S, Rosen MI, O'Malley SS. 1999. Naloxone challenge in smokers: preliminary evidence of an opioid component in nicotine dependence. Archives of General Psychiatry 56:663-668.
113. Krystal JH, D'Souza DC, Madonick S, Petrakis IL. 1999. Toward a rational pharmacotherapy of comorbid substance abuse in schizophrenic patients. Schizophrenia Research 35:S35-S49.
114. Leith NJ, Barrett RJ. 1976. Amphetamine and the reward system: evidence for tolerance and post-drug depression. Psychopharmacologia 46:19-25.
115. Leonard S, Adams C, Breese CR, Adler LE, Bickford P, Byerley W, Coon H, Griffith JM, Miller C, Myles-Worsley M, Nagamoto HT, Rollins Y, Stevens KE, Waldo M, Freedman R. 1996. Nicotinic receptor function in schizophrenia. Schizophrenia Bulletin 22:431-445.
116. Li X, Rainnie DG, McCarley RW, Greene RW. 1998. Presynaptic nicotinic receptors facilitate monaminergic transmission. Journal of Neuroscience 18:1904-1912.
117. Lin, D, Koob GF, Markou A. (1999). Differential effects of withdrawal from chronic amphetamine or fluoxetine administration on brain stimulation reward in the rat: Interactions between the two drugs. Psychopharmacology 145:283-294.
118. Malin DH, Lake JR, Newlin-Maultsby P, Roberts LK, Lanier JG, Carter VA, Cunningham JS, Wilson OB. 1992. Rodent model of nicotine abstinence syndrome. Pharmacology, Biochemistry and Behavior 43:779-784.
119. Malin DH, Lake JR, Carter VA, Cunningham JS, Wilson OB. 1993. Naloxone precipitates nicotine abstinence syndrome in the rat. Psychopharmacology 112:339-342.
120. Malin DH, Lake JR, Carter VA, Cunningham JS, Hebert KM, Conrad DL, Wilson OB. 1994. The nicotinic antagonist mecamylamine precipitates nicotine abstinence syndrome in the rat. Psychopharmacology 115:180-184.
121. Malin DH, Lake JR, Short PE, Blossman JB, Lawless BA, Schopen CK, Sailer EE, Burgess K, Wilson OB. 1996. Nicotine abstinence syndrome precipitated by an analog of neuropeptide FF. Pharmacology, Biochemistry and Behavior 54:581-585.
122. Malin DH, Lake JR, Upchurch TP, Shenoi M, Rajan N, Schweinle WE. 1998. Nicotine abstinence syndrome precipitated by the competitive nicotinic antagonist dihydro-beta-erythroidine. Pharmacology, Biochemistry and Behavior 60:609-613.
123. Marder SR, Wirshing WC, Van Putten T. 1991. Drug treatment of schizophrenia: overview of recent research. Schizophrenia Research 4:81-90.
124. Markou A, Koob GF. 1991. Postcocaine anhedonia: an animal model of cocaine withdrawal. Neuropsychopharmacology 4:17-26.
125. Markou A, Kosten TR, Koob GF. 1998. Neurobiological similarities in depression and drug dependence: a self-medication hypothesis. Neuropsychopharmacology 18:135-174.
126. Marks MJ, Pauly JR, Gross SD, Deneris ES, Hermans-Borgmeyer I, Heinemann S, Collins AC. 1992. Nicotine binding and nicotinic receptor subunit RNA after chronic nicotine treatment. Journal of Neuroscience 12:2765-2784.
127. Marshall DL, Redfern PH, Wonnacott S. 1997. Presynaptic nicotinic modulation of dopamine release in the three ascending pathways studied by in vivo microdialysis: comparision of naive and chronic nicotine-treated rats. Journal of Neurochemistry 68:1511-1519.
128. McGehee DS, Heath MJS, Gelber S, Devay P, Role L. 1995. Nicotine enhancement of fast excitatory synaptic transmission in CNS by presynaptic receptors. Science 269:1692-1696.
129. Menza MA, Grossman N, Van Horn M, Cody R, Forman N. 1991. Smoking and movement disorders in psychiatric patients. Biological Psychiatry 30:109-115.
130. Miyamoto M, Ishida M, Shinozaki H. 1997. Anticonvulsive and neuroprotective actions of a potent agonist (DCG-IV) for group II metabotropic glutamate receptors against intraventricular kainate in the rat. Neuroscience 77:131-140.
131. Moller HJ. 1998. Novel antipsychotics and negative symptoms. International Clinical Psychopharmacology 13:S43-S47.
132. Moolten M, Kornetsky C. 1990. Oral self-administration of ethanol and not experimenter-administered ethanol facilitates rewarding electrical brain stimulation. Alcohol 7:221-225.
133. Mosner A, Kuhlman G, Roehm C, Vogel WH. 1997. Serotonergic receptors modify the voluntary intake of alcohol and morphine but not of cocaine and nicotine by rats. Pharmacology 54:186-192.
134. Nemeth-Coslett R, Griffiths RR. 1986. Naloxone does not affect cigarette smoking. Psychopharmacology 89:261-264.
135. Nides MA, Rakos RF, Gonzales D, Murray RP, Tashkin DP, Bjornson-Benson, WM, Lindgren, P, Connett JE. 1995. Predictors of initial smoking cessation and relapse through the first two years of the Lung Health Study. Journal of Consulting and Clinical Psychology 63:60-69.
136. Nisell M, Nomikos GG, Svensson TH. 1994. Systemic nicotine induced dopamine release in the rat nucleus accumbens is regulated by nicotinic receptors in the ventral tegmental area. Synapse 16:36-44.
137. Nisell M, Nomikos GG, Svensson TH. 1995. Nicotine dependence, midbrain dopamine systems and psychiatric disorders. Pharmacology and Toxicology 76:157-162.
138. Nisell M, Marcus M, Nomikos GG, Svensson TH. 1997. Differential effects of acute and chronic nicotine on dopamine output in the core and shell of the rat nucleus accumbens. Journal of Neural Transmission 104:1-10.
139. Olale F, Gerzanich V, Kuryatov R, Wang F, Lindstrom J. 1997. Chronic nicotine exposure differentially affects the function of human α3, α4, and α7 neuronal nicotinic receptor subtypes. Journal of Pharmacology and Experimental Therapeutics 283:675-683.
140. Olincy A, Young DA, Freedman R. 1997. Increased levels of nicotine metabolite cotinine in schizophrenic smokers compared to other smokers. Biological Psychiatry 42:1-5.
141. Panagis G, Hildebrand BE, Svensson TH, Nomikos GG. 1998. Selective c-fos induction and a decrease in dopamine release in the central nucleus of amygdala in rats displaying a mecamylamine-precipitated nicotine withdrawal syndrome. Society for Neuroscience Abstracts 24:750.
142. Perry DC, Davila-Garcia MI, Stockmeier CA, Kellar KJ. 1999. Increased nicotinic receptors in brains from smokers: membrane binding and autoradiography studies. Journal of Pharmacology and Experimental Therapeutics 289:1545-1552.
143. Picciotto MR, Zoli M, Lena C, Bessis A, Lallemand Y, LeNovere N, Vincent P, Pich EM, Brulet P, Changeux JP. 1995. Abnormal avoidance learning in mice lacking functional high-affinity nicotine receptor in the brain. Nature 374:65-67.
144. Picciotto MR, Zoli M, Rimondini R, Lena C, Marubio E, Merlo-Pich E, Fuxe K, Changeux JP. 1998. Acetylcholine receptors containing the beta2 subunit are involved in the reinforcing properties of nicotine. Nature 391:173-177.
145. Pich EM, Lorang M, Yeganeh M, Rodriguez de Fonseca F, Raber J, Koob GF, Weiss F. 1996. Increase of extracellular corticotropin-releasing factor-like immunoreactivity levels in the amygdala of awake rats during restraint stress and ethanol withdrawal as measured by microdialysis. Journal of Neuroscience 15:5439-5447.
146. Pich EM, Pagliusi SR, Tessari M, Talabot-Ayer D, Hooft van Huijsduijnen R, Chiamulera C. 1997. Common neural substrates for the addictive properties of nicotine and cocaine. Science 275:83-86.
147. Pidoplichko VI, DeBiasi M, Williams JT, Dani JA. 1997. Nicotine activates and desensitizes midbrain dopamine neurons. Nature 390:401-404.
148. Pierzchala K, Houdi AA, VanLoon GR. 1987. Nicotine-induced alterations in brain regional concentrations of native and cryptic metand leu-enkephalin. Peptides 8:1035-1043.
149. Pin JP, Duvoisin R. 1995. The metabotropic glutamate receptors: structure and functions. Neuropharmacology 34:1-26.
150. Pomerleau CS, Pomerleau OF. 1992. Euphoriant effects of nicotine in smokers. Psychopharmacology 108:460-465.
151. Pomerleau OF. 1998. Endogenous opioids and smoking: a review of progress and problems. Psychoneuroendocrinology 23:115-130.
152. Pomerleau OF, Pomerleau CS. 1984. Neuroregulators and the reinforcement of smoking: towards a biobehavioral explanation. Neuroscience and Biobehavioral Reviews 8:503-513.
153. Pomerleau OF, Rosecrans J. 1989. Neuroregulatory effects of nicotine. Psychoneuroendocrinology 14:407-423.
154. Pomerleau OF, Adkins D, Pertschuk M. 1978. Predictors of outcome and recidivism in smoking cessation treatment. Addictive Behaviors 3:65-70.
155. Pontieri FE, Passarelli F, Calo L, Caronti B. 1998. Functional correlates of nicotine administration: similarity with drugs of abuse. Journal of Molecular Medicine 76:193-201.
156. Pontieri FE, Tanda G, Orzi F, Di Chiara G. 1996. Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs. Nature 382:255-257.
157. Prochazka AV, Weaver MJ, Keller RT, Fryer GE, Licari PA, Lofaso D. 1998. A randomized trial of nortriptyline for smoking cessation. Achives of Internal Medicine 158:2035-2039.
158. Rapier C, Lunt GG, Wonnacott S. 1990. Nicotinic modulation of [3H] dopamine release from striatal synaptosomes: pharmacological characterisation. Journal of Neurochemistry 54:937-945.
159. Rasmussen K, Czachura JF. 1995. Nicotine withdrawal leads to increased firing rates of midbrain dopamine neurons. Neuroreport 7:329-332.
160. Rasmussen K, Czachura JF, Kallman MJ, Helton DR. 1996. The CCK-B antagonist LY288513 blocks the effects of nicotine withdrawal on auditory startle. Neuroreport 7:1050-1052.
161. Rasmussen K, Kallman MJ, Helton DR. 1997. Serotonin-1A antagonists attenuate the effects of nicotine withdrawal on the auditory startle response. Synapse 27:145-152.
162. Reitstetter R, Lukas RJ, Gruener R. 1999. Dependence of nicotinic acetylcholine receptor recovery from desensitization on the duration of agonist exposure. Journal of Pharmacology and Experimental Therapeutics 289:656-660.
163. Ribeiro EB, Bettiker RL, Bogdanov M, Wurtman RJ. 1993. Effects of systemic nicotine on serotonin release in rat brain. Brain Research 621:311-318.
164. Richter RM, Weiss F. 1999. In vivo CRF release in rat amygdala is increased during cocaine withdrawal in self-administrating rats. Synapse 32:254-261.
165. Roberts DCS, Koob GF. 1982. Disruption of cocaine self-administration following 6-hydroxydopamine lesions of the ventral tegmental area in rats. Pharmacology, Biochemistry and Behavior 17:901-904.
166. Roberts DCS, Koob GF, Klonoff P, Fibiger HC. 1980. Extinction and recovery of cocaine self-administration following 6-hydroxydopamine lesion of the nucleus accumbens. Pharmacology, Biochemistry and Behavior 12:781-787.
167. Rodriguez de Fonseca F, Carrera MRA, Navarro M, Koob GF, Weiss F. 1997. Activation of cortiotropin-releasing factor in the limbic system during cannabinoid withdrawal. Science 276:2050-2054.
168. Rossetti ZL, Hmaidan Y, Gessa GL. 1992. Marked inhibition of mesolimbic dopamine release: a common feature of ethanol, morphine, cocaine, and amphetamine abstinence in rats. European Journal of Pharmacology 221:227-234.
169. Russell MA. 1989. Subjective and behavioural effects of nicotine in humans: some sources of individual variation. Progress in Brain Research 79:289-302.
170. Sandyk R. 1993. Cigarette smoking: effects on cognitive functions and drug-induced parkinsonism in chronic schizophrenia. International Journal of Neuroscience 70:193-197.
171. Sargent PB. 1993. The diversity of neuronal nicotinic acetylcholine receptors. Annual Review of Neuroscience 16:403-443.
172. Sarnyai Z, Biro E, Gardi J, Vecsernyes M, Julesz J, Telegdy G. 1995. Brain corticotropin-releasing factor mediates 'anxiety-like' behavior induced by cocaine withdrawal in rats. Brain Research 675:89-97.
173. Schilstrom B, Nomikos GG, Nisell M, Hertel P, Svensson TH. 1998. N-methyl-aspartate receptor antagonism in the ventral tegmental area diminishes the systemic nicotine-induced dopamine release in the nucleus accumbens. Neuroscience 82:781-789.
174. Schulteis G, Markou A, Cole M, Koob GF. 1995. Decreased brain reward produced by ethanol withdrawal. Proceedings of the National Academy of Sciences USA 92:5880-5884.
175. Schulteis G, Markou A, Gold LH, Stinus L, Koob GF. 1994. Relative sensitivity to naloxone of multiple indices of opiate withdrawal: a quantitative dose-response analysis. Journal of Pharmacology and Experimental Therapeutics 271:1391-1398.
176. Schwartz RD, Lehmann J, Kellar KJ. 1984. Presynaptic nicotinic cholinergic receptors labeled by [3H]acetylcholine on catecholamine and serotonin axons in the brain. Journal of Neurochemistry 42:1495-1498.
177. Segal DS, Mandell AJ. 1974. Long-term administration of d-amphetamine: progressive augmentation of motor activity and stereotypy. Pharmacology, Biochemistry and Behavior 2:249-255.
178. Seguela P, Wadiche J, Dineley-Miller K, Dani JA, Patrick JW. 1993. Molecular cloning, functional properties, and distribution of rat brain alpha7: a nicotinic cation channel highly permeable to calcium. Journal of Neuroscience 13:596-604.
179. Sellers EM, Naranjo C, Kadlec K. 1987. Do serotonin uptake inhibitors decrease smoking? Observations in a group of heavy smokers. Journal of Clinical Psychopharmacology 7:417-420.
180. Shiffman SM, Jarvik ME. 1976. Smoking withdrawal symptoms in two weeks of abstinence. Psychopharmacology 50:35-39.
181. Shoaib M, Stolerman IP. 1996. The NMDA antagonist dizocilpine (MK-801) attenuates tolerance to nicotine in rats. Journal of Psychopharmacology 10:214-218.
182. Shoaib M, Benwell ME, Akbar MT, Stolerman IP, Balfour DJ. 1994. Behavioral and neurochemical adaptations to nicotine in rats: influence of NMDA antagonists. British Journal of Pharmacology 111:1073-1080.
183. Shoaib M, Schindler CW, Goldberg SR, Pauly JR. 1997. Behavioral and biochemical adaptations to nicotine in rats: influence of MK-801, an NMDA receptor antagonist. Psychopharmacology 134:121-130.
184. Solomon RL, Corbit JD. 1974. An opponent-process theory of motivation, I: temporal dynamics of affect. Psychological Review 81:119-145.
185. Spanagel R, Almeida OFX, Bartl C, Shippenberg TS. 1994. Endogenous κ-opioid systems in opiate withdrawal: role in aversion and accompanying changes in mesolimbic dopamine release. Psychopharmacology 115:121-127.
186. Stahl SM. 1997. Essential Psychopharmacology. New York: Cambridge University Press, pp. 185-188.
187. Steinbusch HW 1981. Distribution of serotonin-immunoreactivity in the central nervous system of the rat-cell bodies and terminals. Neuroscience 6:557-618.
188. Stellar JR, Rice MB. 1989. Pharmacological basis of intracranial self-stimulation reward. In Liebman JM, Cooper SJ, eds. The Neuropharmacological Basis of Reward. Oxford: Clarendon Press, pp. 14-65.
189. Stevens KE, Johnson RG, Rose GM. 1997. Rats reared in social isolation show schizophrenia-like changes in auditory gating. Pharmacology, Biochemistry and Behavior 58:1031-1036.
190. Stolerman IP, Bunker P, Jarvik ME. 1974. Nicotine tolerance in rats: role of dose and dose interval. Psychopharmacologia 34:317-324.
191. Stolerman IP. 1991. Behavioural pharmacology of nicotine: multiple mechanisms. British Journal of Addiction 86:533-536.
192. Stolerman IP, Jarvis MJ. 1995. The scientific case that nicotine is addictive. Psychopharmacology 117:2-10.
193. Stolerman IP, Fink R, Jarvik ME. 1973. Acute and chronic tolerance to nicotine as measured by activity in rats. Psychopharmacologia 30:329-342.
194. Substance Abuse and Mental Health Services Administration. 1993. National Household Survey on Drug Abuse: Population Estimates 1992. Substance Abuse and Mental Health Services Administration, Office of Applied Studies, Table 14A. Rockville, MD.
195. Svensson TH, Grenhoff J, Engberg G. 1990. Effect of nicotine on dynamic function of brain catecholaminergic neurons. In: The Neurobiology of Nicotine Dependence (Series title: Ciba Foundation Symposium, Vol. 152). Wiley:Chichester, pp. 169-185.
196. Swan GE, Ward MM, Jack LM. 1996. Abstinence effects as predictors of 28-day relapse in smokers. Addictive Behaviors 21:481-490.
197. Swanson LW, Simmons DM, Whiting PJ, Lindstrom J. 1987. Immunohistochemical localization of neuronal nicotinic receptors in the rodent central nervous system. Journal of Neuroscience 7:3334-3342.
198. Swerdlow NR, Geyer MA. 1993. Clozapine and haloperidol in an animal model of sensorimotor gating deficits in schizophrenia. Pharmacology, Biochemistry and Behavior 44:741-744.
199. Swerdlow NR, Geyer MA. 1998. Using an animal model of deficient sensorimotor gating to study the pathophysiology and new treatments of schizophrenia. Schizophrenia Bulletin 4:285-301.
200. Swerdlow NR, Braff DL, Geyer MA, Koob GF. 1986. Central dopamine hyperactivity in rats mimics abnormal acoustic startle response in schizophrenics. Biological Psychiatry 21:23-33.
201. Swerdlow NR, Braff DL, Geyer MA. 1990. GABAergic projection from nucleus accumbens to ventral pallidum mediates dopamine-induced sensorimotor gating deficits of acoustic startle in rats. Brain Research 532:146-150.
202. Swerdlow NR, Caine SB, Geyer MA. 1992. Regionally selective effects of intracerebral dopamine infusion on sensorimotor gating of the startle reflex in rats. Psychopharmacology 108:189-195.
203. Sziraki I, Sershen H, Benuck M, Hashim A, Lajtha A. 1998. Receptor systems participating in nicotine-specific effects. Neurochemistry International 33:445-457.
204. Tempel A, Zukin RS. 1987. Neuroanatomical patterns of the mu, delta, and kappa opioid receptors of rat brain as determined by quantitative in vitro radiography. Proceedings of the National Academy of Sciences USA 84:4308-4312.
205. Terenius L. 1992. Opioid peptides, pain and stress. Progress in Brain Research 92:375-383.
206. Trujillo KA, Akil H. 1995. Excitatory amino acids and drugs of abuse: a role for N-methyl-aspartate receptors in drug tolerance, sensitization, and physical dependence. Drug and Alcohol Dependence 38:139-154.
207. United States Department of Health and Human Services. 1988. The Health Consequences of Smoking: Nicotine Addiction. A report of the Surgeon General. US Government Printing Office, Washington, D.C.
208. Usuda I, Tanaka K, Chiba T. 1998. Efferent projections of the nucleus accumbens in the rat with special reference to subdivision of the nucleus: biotinylated dextran amine study. Brain Research 797:73-93.
209. Waal-Manning HJ, de Hamel FA. 1978. Smoking habit and psychometric scores: a community study. New Zealand Medical Journal 88:188-191.
210. Wada E, Wada K, Boulter J, Deneris E, Heinemann S, Patrick J, Swanson LW 1989. Distribution of alpha2, alpha3, alpha4, and beta2 neuronal nicotinic receptor subunit mRNAs in the central nervous system: a hybridization histochemical study in the rat. Journal of Comparative Neurology 284:314-355.
211. Walaas I, Fonnum F. 1980. Biochemical evidence for gamma-aminobutryate containing fibers from the nucleus accumbens to the substantia nigra and ventral tegmental area in the rat. Neuroscience 5:63-72.
212. Watkins SS, Epping-Jordan M, Koob GF, Markou A. 1999. Blockade of nicotine self-administration with nicotinic antagonists in rats. Pharmacology, Biochemistry and Behavior 62:743-751.
213. Watkins SS, Stinus L, Koob GF, Markou A. 2000. Reward and somatic changes during precipitated nicotine withdrawal in the rat: central and peripheral mechanisms. Journal of Pharmacology and Experimental Therapeutics, 292:1053-1064.
214. Weinberger DR, Berman KF, Illowsky BP. 1988. Physiological dysfunction of dorsolateral prefrontal cortex in schizophrenia, III: a new cohort and evidence for a monoaminergic mechanism. Archives of General Psychiatry 45:609-615.
215. Weiss F, Markou A, Lorang MT, Koob GF. 1992. Basal extracellular dopamine levels in the nucleus accumbens are decreased during cocaine withdrawal after unlimited-access self-administration. Brain Research 593:314-318.
216. Weiss F, Parsons LH, Schulteis G, Hyytia P, Lorang MT, Bloom FE, Koob GF. 1996. Ethanol self-administration restores withdrawal-associated deficiencies in accumbal dopamine and 5-hydroxytryptamine release in dependent rats. Journal of Neuroscience 16:3474-3485.
217. Wiley JL. 1998. Nitric oxide synthase inhibitors attenuate phencyclidine-induced disruption of prepulse inhibition. Neuropsychopharmacology 19:86-94.
218. Wirshing WC, Engle J, Levin E, Cummings JL, Rose J. 1989. The acute effects of smoking on tardive dyskinesia. New Research Program and Abstracts, 142nd Annual Meeting of the American Psychiatric Association, San Francisco, CA.
219. Wonnacott S. 1990. The paradox of nicotinic acetylcholine receptor upregulation by nicotine. Trends in Pharmacological Sciences 11:216-219.
220. Wonnacott S. 1997. Presynaptic nicotinic ACh receptors. Trends in Neurosciences 20:92-98.
221. Yassa R, Lal S, Korpassy A, Ally J. 1987. Nicotine exposure and tardive dyskinesia. Biological Psychiatry 22:67-72.
222. Yeomans J, Baptista M. 1997. Both nicotinic and muscarinic receptors in the ventral tegmental area contribute to brain-stimulation reward. Pharmacology, Biochemistry and Behavior 57:915-921.
223. Yeomans J, Mathur A, Tampakeras M. 1993. Rewarding brain stimulation: role of tegmental cholinergic neurons that activate dopamine neurons. Behavioral Neuroscience 107:1077-1087.
224. Yim CY, Mogenson GJ. 1980. Electrophysiological studies of neurons in the ventral tegmental area of Tsai. Brain Research 181:301-313.
225. Young SN, Smith SE, Pihl RO, Ervin FR. 1985. Tryptophan depletion causes a rapid lowering of mood in normal males. Psychopharmacology 87:173-177.
226. Zoli M, Lena C, Picciotto MR, Changeux JP. 1998. Identification of four classes of brain nicotinic receptors using β2 mutant mice. Journal of Neuroscience 18:4461-4472.